Agios ( AGIO ) Q2 Revenue Jumps 45%
Agios Pharmaceuticals ( NASDAQ:AGIO ) , a biotechnology company focused on therapies for rare blood disorders, released its second quarter 2025 earnings on July 31, 2025. The headline was a notable revenue beat: This quarter showcased clear progress on sales for its lead product PYRUKYND, with ...
Agios Pharmaceuticals ( AGIO ) Reports Q2 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -10.92% and +34.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
Agios Pharmaceuticals today announced financial results and updates for the second quarter ended June 30, 2025.
Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET - Agios Pharmaceuticals ( NASDAQ:AGIO )
CAMBRIDGE, Mass., July 14, 2025 ( GLOBE NEWSWIRE ) -- Agios Pharmaceuticals, Inc. AGIO, a leader in cellular metabolism and pyruvate kinase ( PK ) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, July 31, ...
Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET
Agios Pharmaceuticals announced it will host a conference call and live webcast on Thursday, July 31, 2025, at 8:00 a.m. ET to report its 2Q results ...
Agios Pharmaceuticals ( AGIO ) Moves 7.7% Higher: Will This Strength Last?
Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Agios Appoints Dr. Jay Backstrom to Board of Directors - Agios Pharmaceuticals ( NASDAQ:AGIO )
CAMBRIDGE, Mass., July 08, 2025 ( GLOBE NEWSWIRE ) -- Agios Pharmaceuticals, Inc. AGIO, a leader in cellular metabolism and pyruvate kinase ( PK ) activation pioneering therapies for rare diseases, today announced the appointment of Jay Backstrom, M.D., M.P.H., to its Board of Directors, ...
AGIO STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Agios Pharmaceuticals, Inc. ( NASDAQ: AGIO ) and Encourages Long-Term Investors to Contact the Firm - Agios Pharmaceuticals ( NASDAQ:AGIO )
PHILADELPHIA, June 26, 2025 ( GLOBE NEWSWIRE ) -- Kaskela Law LLC announces that it is investigating Agios Pharmaceuticals, Inc. AGIO ( "Agios" ) on behalf of the company's long-term investors.
X-Chem Strengthens Executive Team with Strategic Finance and HR Appointments
WALTHAM, Mass., June 17, 2025 ( GLOBE NEWSWIRE ) -- X-Chem, a global leader in data-driven drug discovery and DNA-encoded library ( DEL ) technology, today announced the appointments of Stephen Fair as Chief Financial Officer and Maureen Hart as Senior Vice President of Human Resources, ...
Ultragenyx ( RARE ) Up 9.6% Since Last Earnings Report: Can It Continue?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Vertex ( VRTX ) Down 0.8% Since Last Earnings Report: Can It Rebound?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 - Agios Pharmaceuticals ( NASDAQ:AGIO )
CAMBRIDGE, Mass., May 28, 2025 ( GLOBE NEWSWIRE ) -- Agios Pharmaceuticals, Inc. AGIO, a leader in cellular metabolism and pyruvate kinase ( PK ) activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the Goldman Sachs 46th Annual ...
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress
Agios Pharmaceuticals will be featured in oral and poster presentations during the 30th European Hematology Association Congress on June 12-15, 2025.
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 - Agios Pharmaceuticals ( NASDAQ:AGIO )
CAMBRIDGE, Mass., May 09, 2025 ( GLOBE NEWSWIRE ) -- Agios Pharmaceuticals, Inc. AGIO, a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 2025 RBC Capital Markets Global Healthcare ...
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
Agios Pharmaceuticals today announced that its management team is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference ...
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates
AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 - Agios Pharmaceuticals ( NASDAQ:AGIO )
CAMBRIDGE, Mass., May 02, 2025 ( GLOBE NEWSWIRE ) -- Agios Pharmaceuticals, Inc. AGIO, a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on ...
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025
Agios Pharmaceuticals today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference ...
Agios Pharmaceuticals ( AGIO ) Reports Q1 Loss, Misses Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 13.89% and 11.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., May 01, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today reports first-quarter 2025 financial results and ...
Analysts Estimate Agios Pharmaceuticals ( AGIO ) to Report a Decline in Earnings: What to Look Out for
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025
Agios to Webcast Conference Call of First Quarter Financial Results on May ...
New Strong Sell Stocks for April 8th
AFLYY, AGIO and ARLP have been added to the Zacks Rank #5 (Strong Sell) List on April 8, 2025.
New Strong Sell Stocks for April 3rd
AGIO, CHGG and EFX have been added to the Zacks Rank #5 (Strong Sell) List on April 3, 2025.
Wave Life Sciences ( WVE ) Stock Jumps 6.1%: Will It Continue to Soar?
Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Auron Therapeutics Expands Leadership with Appointment of Glenn Goddard as Chief Financial Officer
NEWTON, Mass., March 19, 2025 ( GLOBE NEWSWIRE ) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced the appointment of Glenn Goddard as Chief Financial Officer.
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) to Newly Appointed Chief Corporate Development & Strategy Officer
CAMBRIDGE, Mass., March 05, 2025 ( GLOBE NEWSWIRE ) -- Agios Pharmaceuticals, Inc. ( Nasdaq: AGIO ) , a leader in cellular metabolism and pyruvate kinase ( PK ) activation pioneering therapies for rare diseases, today announced the grant of inducement equity awards outside of the Company's 2023 ...
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025 - Agios Pharmaceuticals ( NASDAQ:AGIO )
CAMBRIDGE, Mass., Feb. 20, 2025 ( GLOBE NEWSWIRE ) -- Agios Pharmaceuticals, Inc. AGIO, a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the TD Cowen 45th Annual Healthcare Conference on ...
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues
AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year.
Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years - Agios Pharmaceuticals ( NASDAQ:AGIO )
Agios' ACTIVATE-Kids trial showed 31.6% of mitapivat-treated children met the hemoglobin response endpoint vs. 0% in the placebo group. Agios reported Q4 Pyrukynd revenue of $10.7M, exceeding the $9.33M consensus, with 130 patients on therapy and cash reserves of $1.5B.
Agios Pharmaceuticals ( AGIO ) Reports Q4 Loss, Tops Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -0.58% and 11.76%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
- Filed for Regulatory Approval of Mitapivat ( PYRUKYND® ) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Arab Emirates. PDUFA Goal Date of September ...
Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase ( PK ) Deficiency Not Regularly Transfused Met Primary Endpoint
- ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused ...
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio - Agios Pharmaceuticals ( NASDAQ:AGIO )
- FDA Accepted Agios' Supplemental New Drug Application for PYRUKYND® ( mitapivat ) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia; PDUFA Goal Date is September 7, 2025 -
FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia
If approved, AGIO's Pyrukynd will be the first oral therapy for all thalassemia subtypes. A final decision is expected by Sep. 7.
FDA Accepts Agios' Supplemental New Drug Application for PYRUKYND® ( mitapivat ) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia - Agios Pharmaceuticals ( NASDAQ:AGIO )
CAMBRIDGE, Mass., Jan. 08, 2025 ( GLOBE NEWSWIRE ) -- Agios Pharmaceuticals, Inc. AGIO, a leader in cellular metabolism and pyruvate kinase ( PK ) activation pioneering therapies for rare diseases, today announced that the U.S.
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 7:30 a.m. PT / 10:30 a.m. ET.
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease
CAMBRIDGE, Mass., Dec. 18, 2024 ( GLOBE NEWSWIRE ) -- Agios Pharmaceuticals, Inc. ( Nasdaq: AGIO ) , a leader in cellular metabolism and pyruvate kinase ( PK ) activation pioneering therapies for rare diseases, today announced that the European Commission has adopted a positive decision for the ...
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday - Aehr Test System ( NASDAQ:AEHR ) , Agios Pharmaceuticals ( NASDAQ:AGIO )
U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 1% on Monday. Shares of Tesla, Inc. TSLA rose sharply during Monday's session after Wedbush maintained an Outperform rating on the stock and raised its price target from $400 to $515. Tesla shares gained 5% to $458.08 on ...
Here's Why Agios Stock Plummeted More Than 20% on Monday
The fall in AGIO stock comes after reports of an unexpected side effect linked to its sole-marketed drug Pyrukynd in thalassemia patients.
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat - Agios Pharmaceuticals ( NASDAQ:AGIO )
- ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia - - ENERGIZE-T is First Phase 3 Study to Demonstrate Efficacy of an Oral, Disease-Modifying Treatment for Transfusion-Dependent Alpha- and Beta-Thalassemia -
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
- ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or ...
Why Is Denali Therapeutics ( DNLI ) Down 21.2% Since Last Earnings Report?
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are Options Traders Betting on a Big Move in Agios ( AGIO ) Stock?
Investors need to pay close attention to Agios (AGIO) stock based on the movements in the options market lately.
Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios
ResMed, Haemonetics, Phibro and Agios have been highlighted in this Industry Outlook article.
4 Medical Product Stocks to Buy From a Prospective Industry
An ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. RMD, HAE, PAHC and AGIO are well-poised to gain from the favorable factors.
Is Agios Pharmaceuticals ( AGIO ) Stock Outpacing Its Medical Peers This Year?
Here is how Agios Pharmaceuticals (AGIO) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience ...
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down
Agios' third-quarter 2024 earnings miss estimates while revenues match the same. Shares fall.
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down
Agios' third-quarter 2024 earnings miss estimates while revenues match the same. Shares fall.
